Back to the main directory
EarningsReview / Equity
- Non material data changes by BNP Paribas Exane
- Work differently in 2024 by BNP Paribas Exane
- ’24 guidance essentially in-line, expense pressures moderating by BNP Paribas Exane
- Solid FY 23 results by BNP Paribas Exane
- Itaú BBA on Televisa: 4Q23 Conference Call Highlights by Itau
- MercadoLibre (MELI US) by HSBC
- Surgical Science (Buy, TP: SEK235.00) - Affected by economic turmoil by DnB Markets
- Sagax (Sell, TP: SEK230.00) - Growth set to slow in H2 2024 by DnB Markets
- Genco Shipping & Trading (Buy, TP: USD22.50) - Consistent market strength by DnB Markets
- Norva24 (Buy, TP: SEK34.00) - Harsh winter a seasonal headwind by DnB Markets
- Valuation and market update by DnB Markets
- Seafood - Fat Trout Weekly by DnB Markets
- Bidcorp Limited (BID SJ) by HSBC
- Embassy Office Park REIT (EMBASSY IN) by HSBC
- Norva24 - A mixed end to the year by Danske Bank Equity Research
- Rebuilding margins and credibility by BNP Paribas Exane
- Hybrid bonding adoption gains steam by BNP Paribas Exane
- Sustainability Weekly 19 – 23 Février 2024 by Oddo BHF
- Solving the Inverter Margin Puzzle by BNP Paribas Exane
- Mixed results - down to Neutral on limited upside by BNP Paribas Exane
- Sustainability Weekly 19 – 23 February 2024 by Oddo BHF
- Recovering to Growth by BNP Paribas Exane
- by BNP Paribas Exane
- INVEST SECURITIES - ALTEN : Publications sans surprise - ACHAT, OC 160€ vs 148€ by Invest Securities
- INVEST SECURITIES - TME PHARMA :Près de 80% des BSA Y exercés, actionnariat engagé - ACHAT, OC 0,62€ vs 0,67€ by Invest Securities